Date of event
-
Location

Washington, District of Columbia United States

Continuing Education Credits
CME
Add to Calendar 2020-03-20 08:00:00 2020-03-21 11:15:00 Emerging Topic Conference: Nuclear Receptors as Common Clinical Targets for the Treatment of Cholestatic and Nonalcoholic Fatty Liver Diseases This conference gathers translational researchers and clinical investigators in cholestatic and/or fatty liver diseases to review preclinical and clinical investigations, and strategize the rapid emergence of novel, efficient therapeutic options. Washington, DC United States AASLD alonzo.tolver@boldrstrategy.com America/New_York public

Registration and conference abstract submitter to open Wednesday, November 20 at 9:00 am ET.

Course Description / Needs Statement

Cholestatic and non-alcoholic fatty liver diseases share some pharmacological targets and potential therapies, including the synthetic FXR agonist, obeticholic acid. FXR activation is intensively evaluated as a treatment option for NAFLD/NASH. This symposium gathers translational researchers and clinical investigators in cholestatic and/or fatty liver diseases to review preclinical and clinical investigations, and strategize the rapid emergence of novel, efficient therapeutic options.

Program Chairs

  • Olivier Barbier, PhD, FAASLD
  • Rohit Loomba, MD
  • Stephen A. Harrison, MD, FAASLD

Location

  • The Westin Crystal City
    1800 Jefferson Davis Hwy
    Arlington, VA 22202

Continuing Education

  • CME – 9.75 AMA PRA Category 1 Credits™

Related Conference Note

Consider registering for the AASLD/EASL NASH and NAFLD Clinical Endpoints Conference, which will take place at the same location on March 21-22, 2020.

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Schedule Note

Breakfast is served at 7:00 am ET both days.

Session I: Pathophysiology of Cholestatic and Fatty Liver Diseases
Moderators: Stephen A. Harrison, MD, FAASLD and Olivier Barbier, PhD, FAASLD

  • 8:00 am – 8:05 am
    Introduction
    Rohit Loomba, MD
  • 8:05 am – 8:25 am
    Physiopathology of NAFLD
    Brent A. Neuschwander-Tetri, MD
  • 8:25 am – 8:45 am
    Physiopathology of Cholestatic Liver Diseases (including PBC, PSC, and AIH)
    Marlyn J. Mayo, MD, FAASLD
  • 8:45 am – 9:05 am
    Histopathology of Cholestatic Versus Fatty Liver Diseases in the Patterns of Inflammation/Fibrosis
    Elizabeth M. Brunt, MD, FAASLD
  • 9:05 am – 9:25 am
    Bile Acid Sensors, and Other Nuclear Receptors: Are the Same Players Involved in Cholestatic and Fatty Liver Diseases?
    David J. Mangelsdorf, PhD
  • 9:25 am – 9:45 am
    Panel Discussion / Q&A
  • 9:45 am – 10:00 am
    Break

Session II: Bile Acids as Therapeutic Agents and Targets: The Past and Future
Moderators: Cynthia Levy, MD, FAASLD and Brent A. Neuschwander-Tetri, MD

  • 10:00 am – 10:20 am
    Bile Acid Sensors and transporters and FXR Agonists in Cholestatic Liver Diseases
    Michael H. Trauner, MD, FAASLD
  • 10:20 am – 10:40 am
    FXR and Other Nuclear/Membrane Receptors in NAFLD
    David A. Brenner, MD
  • 10:40 am – 11:00 am
    Control of Metabolism by Intestinal FXR
    Ronald M. Evans, PhD
  • 11:00 am – 11:30 am
    Panel Discussion / Q&A
  • 11:30 am – 1:00 pm
    Lunch and Poster Session

Session III: PPARs: The Old Emerging Therapeutic Targets
Moderators: Saul J. Karpen, MD, PhD, FAASLD and Kathleen E. Corey, MD, MPH, MMSc

  • 1:00 pm – 1:20 pm
    PPARs and Bile Acid and Fatty Acid Metabolism
    Olivier Barbier, PhD, FAASLD
  • 1:20 pm – 1:40 pm
    Fibrates in Cholestatic Liver Diseases
    David Assis, MD
  • 1:40 pm – 2:00 pm
    New PPAR Agonists for Cholestatic and Fatty Liver Diseases
    Bart Staels, PhD
  • 2:00 pm – 2:10 pm
    Oral Presentation #1
  • 2:10 pm – 2:20 pm
    Oral Presentation #2
  • 2:20 pm – 2:40 pm
    Break

Session IV: Diagnostic and Prognostic Markers in Cholestasis and NAFLD
Moderators: Stephen A. Harrison, MD, FAASLD and Christopher L. Bowlus, MD, FAASLD

  • 2:40 pm – 3:00 pm
    Defining Response to Treatment in Cirrhotic NASH
    Manal F. Abdelmalek, MD, MPH, FAASLD
  • 3:00 pm – 3:20 pm
    Endpoints for Registration Trials in NASH and Cholestatic Liver Diseases
    Lara L. Dimick-Santos, MD
  • 3:20 pm – 3:40 pm
    Bile Acid Physiology and Pathobiology: What Can Pediatric Genetic Cholestatic Diseases Teach Us
    Saul J. Karpen, MD, PhD, FAASLD
  • 3:40 pm – 4:00 pm
    Surrogate Markers in Cholestatic Liver Diseases
    Christopher L. Bowlus, MD, FAASLD
  • 4:00 pm – 4:30 pm
    Panel Discussion / Q&A

Session V: Targeting the Microbiome in AILD and NAFLD
Moderators: Bernd Schnabl, MD, FAASLD and Ariel E. Feldstein, MD

  • 8:00 am – 8:20 am
    The Microbiome in Animal Models of NAFLD and Cholestatic Liver Diseases: What Do We Already Know?
    Bernd Schnabl, MD, FAASLD
  • 8:20 am – 8:40 am
    Microbiomics and Cholestatic Liver Diseases
    Alexander G. Miethke, MD
  • 8:40 am – 9:00 am
    Clinical and Translational Studies in Microbiome and NAFLD: Current and Future
    Rohit Loomba, MD
  • 9:00 am – 9:10 am
    Oral Abstract Presentation #3
  • 9:10 am – 9:20 am
    Oral Abstract Presentation #4
  • 9:20 am – 9:40 am
    Panel Discussion / Q&A
  • 9:40 am – 10:00 am
    Break

Session VI: Integrative Session: Future Common Treatment for Autoimmune Liver Diseases and NAFLD
Moderators: Rohit Loomba, MD and Ronald J. Sokol, MD, FAASLD

  • 10:00 am – 10:20 am
    Design of Future Trials: Can Fatty Liver and Cholestatic Diseases Benefit From Each Other?
    Stephen A. Harrison, MD, FAASLD
  • 10:20 am – 10:40 am
    Beyond Bile Acids and Nuclear Receptors: Other Emerging Treatments for PBC, PSC and NAFLD
    Kathleen E. Corey, MD, MPH, MMSc
  • 10:40 am – 11:00 am
    Is the Intestine the Future of Bile Acid Treatment?
    Ronald J. Sokol, MD, FAASLD
  • 11:00 am – 11:15 am
    Wrap-up
    Stephen A. Harrison, MD, FAASLD
  • 11:15 am
    Adjourn

US Residents: Review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Venue

The Westin Crystal City
1800 Jefferson Davis Hwy
Arlington, VA 22202

Make your Online Reservations
Phone: 703-486-1111

If you are calling to make a reservation, let the hotel representative know you are attending the AASLD meeting.

Rates

Single/Double $169 per night plus tax

Cancellation Policy

All hotel room reservations must be cancelled within 48 hours of scheduled arrival date to receive a refund.

Airports

  • Ronald Reagan National Airport (DCA)
  • Washington Dulles International Airport (IAD)

Ground Transportation

Shuttle Services
Complimentary shuttle services to the hotel are provided from 5:30 am – 11:00 pm daily to and from the DCA airport. If using this option, stand by the hotel shuttle pick up outside of the airport.

There is no shuttle service from the IAD airport.

Taxi
From DCA the taxi fare estimation is $12 (one way) and from IAD is $65. Both are estimations for one-way fares.

Metro / Subway / Public Transportation
The nearest WMATA metro station is the Crystal City Metro Station (both Blue and Yellow lines). The metro station is .1 miles from the Westin Crystal City Hotel. The estimated metro fare from DCA is $2.25 and from IAD is $6. Both reflect one-way fares.

Parking

Self-parking at the hotel is $16 hourly and $34 daily. Valet parking fee is $40 daily.

Needs Statement

Cholestatic and non-alcoholic fatty liver diseases share some pharmacological targets and potential therapies, including the synthetic FXR agonist, obeticholic acid. FXR activation is intensively evaluated as a treatment option for NAFLD/NASH. This symposium gathers translational researchers and clinical investigators in cholestatic and/or fatty liver diseases to review preclinical and clinical investigations, and strategize the rapid emergence of novel, efficient therapeutic options.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Increase understanding of autoimmune and fatty liver diseases to be more efficient in identifying current or future therapies for patients
  • Enhance knowledge and understanding of autoimmune and fatty liver diseases to be informed of the most recent basic discoveries in the field
  • Improve their knowledge and understanding of autoimmune and fatty liver diseases.

Target Audience

  • Gastroenterologists
  • Nurses
  • Pharmacists
  • Physician Assistants
  • Surgeons
  • Fellows/Trainees
  • Basic Scientists
  • Graduate Students
  • Post-docs
  • Patients Association

This activity was planned in the context of the following ACGME/IOM/IPEC competencies:

  • Evidence-based Practice
  • Medical Knowledge
  • Provide Patient-centered Care
  • Professionalism

Credits Offered

  • Continuing Medical Education (CME): 9.75 AMA PRA Category 1 Credits™

Accreditation and Designation Statements

Continuing Medical Education (CME)

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Credits

Physicians and other health care professionals seeking 9.75 AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Tuesday, April 21. A link to the CME evaluation will be emailed to attendees after the conference.

Submission Deadlines

  • Opens: Wednesday, November 20, 2019
  • Closes: Friday, January 17, 2020

Overview

Abstracts submitted will be reviewed by the Program Chairs for potential poster presentation. If selected, the presenting author will be required to accept the invitation to present, register for the conference, and provide current financial disclosure information.

Abstract notification will be sent to presenting authors by mid-February.

Questions

For questions about the abstract submission process, send an email to abstracts@aasld.org.

Title

The title should be brief, but long enough to identify the nature of the study. Omit author names and medical degrees and institutional appointments in the title. The maximum for the title character count is 300.

Abstract Body

The body of the abstract needs to include:

  • A background
  • Description of methods
  • Summary of results obtained
  • Statement of conclusion reached

There is a set 3,000 maximum character count for the abstract body.

Attachments

You may include any supporting images/tables. Images and tables are not a part of the overall character count.
Accepted files: pdf, jpg, jpeg, png, csv, doc(x), and ppt under 5MB

Author Types

Only one presenting and corresponding author may be selected – see author definitions below

  • Co-Author – One of several authors who provided a significant contribution to the abstract.
  • Corresponding Author – This author will receive all notifications regarding the abstract, and will be expected to make any changes requested by the abstract reviewers.
  • Presenting Author – The author who will be presenting the poster at the meeting.

The maximum number of authors on an abstract is 30.

Questions

For questions about the abstract submission process, send an email to abstracts@aasld.org.

Ethics Policy

The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD meetings or journals. First, for reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials. HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.

Second, in studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals [PDF] prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

Disclosure Policy

It is the policy of the American Association for the Study of Liver Diseases (AASLD) to ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided educational programs. All faculty/authors participating in any AASLD sponsored programs, as well as planners and committee members, are expected to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education program.

All abstract authors must complete their own financial disclosure statement either disclosing all financial relationships with commercial interests or indicating that none exist. Submitting authors will NOT be allowed to submit disclosures on a co-author's behalf.

A limited number of travel awards will be available for trainees in the field of hepatology with a special interest in the conference topic. In order to qualify for a travel award, an abstract on related research must be submitted and accepted.

Press Policies and Guidelines

The American Association for the Study of Liver Diseases provides credentialed media with complimentary press registration. Below is information on eligibility and the credentialing process.

Press Eligibility

Journalists, and contributing freelancers, employed by a recognized news organization are eligible to apply for press registration. To be eligible for press registration, media in all categories must be directly involved in the creation of news content for organizations that meet these criteria:

  • Publish original editorial news coverage in a regular news section
  • Have complete editorial freedom from advertisers, funders and/or sponsors
  • If sponsored, the outlet has multiple sponsors (no single-sponsored publications)
  • Advertisers, sponsors, paid editorial and other funding sources are clearly identified

Bloggers

Bloggers will receive press credentials on a case-by-case basis. Please include a link to recent liver disease, hepatology or health care science coverage with your registration for credentials. Finally, all blogs must demonstrate the dissemination of original, editorial news coverage and editorial freedom from advertisers and/or sponsors (single-sponsored blogs will not receive credentials; blogs with advertising must have multiple advertisers clearly identified).

Photographers/Videographers

Photographers, videographers, and/or other members of the multimedia team accompanying credentialed news outlets may register as media and provide a link to recent coverage from their team. Further credentialing may be required during the approval process.

NOTE: AASLD has the right to inspect the credentials of anyone registering as media and reserves the right to deny media registration to anyone who does not meet the above guidelines. AASLD also has the right to limit the number of media registrants from any one media outlet to ensure ample space for all media.

Ineligible Registrants

The following individuals are not eligible for press registration or access to the Newsroom:

  • Individuals who receive exhibitor passes
  • Publishers or a publications’ advertising, marketing, public relations, sales, circulation, or any other non-editorial function representatives
  • Industry/exhibitor press officers and their public relations consultants
  • Financial or business analysts
  • Educational program developers (including CME writers and editors)
  • Trade media management personnel
  • Editors, writers, and scientific advisory board members for journals that do not have editorial news sections
  • Companies or organizations producing publications, videos, and/or other electronic media intended for internal use, marketing, advertising, financial analysis, or public relations purposes
  • Media who produce a communications vehicle that is sponsored by a single organization or whose revenue for the publication or issue of a publication depends solely on coverage of 2020 AASLD Emerging Topic Conference, Nuclear Receptors as Common Clinical Targets for the Treatment of Cholestatic and Nonalcoholic Fatty Liver Diseases
  • Media who produce a communications vehicle that uses the AASLD’s name or logo, or the Emerging Topic Conference name/logo to imply endorsement from AASLD

NOTE: AASLD prohibits the development of CME content based on information presented at its meetings. CME writers and editors, and those writers and editors working on behalf of organizations that have written CME based on AASLD meetings, are not eligible for press passes.

Prohibited Activities

  • Sales, marketing or representing a company for the purposes of obtaining advertising, subscriptions, selling photography/video production, or other products or services from any registrant or exhibitor
  • Misrepresentation of role or activities to obtain media registration
  • Developing or assisting in the development of continuing medical education programs
  • Soliciting presenters and/or attendees for inclusion in CME programs
  • Publishing or posting presentation slides, live streams of meeting presentations, or sharing copyrighted meeting materials without written permission.

Video/Audio Recording

Television and video crews are required to check in immediately with AASLD staff each day.

Television and video crews must be wearing press badges. Shooting schedules must be provided to AASLD staff in advance of the meeting.

Permission of the speaker and moderator must be obtained by the journalist before recording or photographing presentations. Artificial light and flash photography cannot be used during presentations. Handheld audio recorders and still cameras are acceptable, assuming that intellectual property copyrights are respected.

Under no circumstances may presentations be rebroadcasted.

Any images from the meeting should be credited to: 2020 AASLD Emerging Topic Conference, Nuclear Receptors as Common Clinical Targets for the Treatment of Cholestatic and Nonalcoholic Fatty Liver Diseases.

Use of Insignias and Logos

Insignias and logos of the AASLD, this meeting or AASLD Foundation are proprietary marks. Use of these in any fashion, by any entity, for any purpose, is prohibited without the written permission of AASLD. The use of insignias, logos and images that mislead the intended audience to believe that a piece or production is coming from the AASLD is strictly prohibited and will result in the denial of press credentials for future meetings.

Dedicated Websites and Newsletters

If you intend to present coverage of this meeting in a dedicated website or newsletter, please include the following disclaimer at the top of your piece: This information is brought to you by [insert organization name] and is not sponsored by, nor a part of, the Association for the Study of Liver Diseases or 2020 AASLD Emerging Topic Conference, Nuclear Receptors as Common Clinical Targets for the Treatment of Cholestatic and Nonalcoholic Fatty Liver Diseases. Additionally, you may not use the AASLD’s logo or name to imply affiliation.

AASLD reserves the right to request promotional activities violating this policy be edited or removed. Failure to comply with these guidelines may result in loss of press credentials for future meetings.

Applying for Press Credentials

Requests for press credentials should be sent to media@aasld.org and must be sent by Friday, March 13, 2020. Onsite press registration cannot be accommodated. When sending your request for credentials, include two of the following:

  • Bylined news coverage
  • Copy of official press credentials
  • Assignment letter
  • Two recent posts about liver disease and/or health care (for bloggers)